Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division

Rhea-AI Summary

Exousia Pro (OTCPINK:MAJI) announced its strategic entry into the telehealth market through an acquisition that will establish its new division, Exousia Health. The acquired telehealth company brings an initial base of 1,000 active clients and projected monthly revenue of $50,000.

The company is reviewing two additional significant contracts expected to boost monthly revenue substantially. Exousia Health also plans to integrate a compounding pharmacy operation, creating a third revenue stream by handling prescriptions from its telehealth doctors directly.

Management expects Exousia Health to become the company's primary revenue generator until its AI division begins licensing cancer therapy technology.

Positive

• Immediate revenue generation of $50,000 monthly from 1,000 active clients
• Two additional significant contracts under review for revenue expansion
• Three diversified revenue streams: telehealth consultations, prescribed regimens, and compounding pharmacy
• Strategic entry into the rapidly growing telehealth market

Negative

• 12-month timeline for contract implementation indicates slow revenue ramp-up
• Revenue dependency on telehealth division until AI technology commercialization
• Acquisition completion still pending and subject to closing conditions

Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue.

ORLANDO, FL / ACCESS Newswire / September 8, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on exosome-based therapies, today announced that it expects to enter into the rapidly growing telehealth market, following its agreement to acquire a telehealth company, which will serve as the foundation of a new division, Exousia Health. Completion of this acquisition is a key step in diversifying the company's future revenue streams.

Following the acquisition closing, Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue. The telehealth company's existing platform and patient roster would immediately contribute to the company's financial performance.

Exousia Health is also in the final stages of a due diligence review of two additional, significant contracts, which are expected to substantially increase monthly revenue. These contracts would generate revenue from both patient-doctor consultations and the markup on doctor-prescribed regimens.

"The telehealth market is experiencing rapid expansion, and this acquisition positions us to be a key player," said Matt Dwyer, President of Exousia Pro, Inc. "We project significant month-over-month revenue growth for Exousia Health, with the two large contracts being onboarded over 12 months to ensure a seamless transition for clients. This methodical approach will enable us to scale our operations effectively. We anticipate that Exousia Health will be our primary revenue driver, until Exousia AI begins to license its cancer therapy technology."

Mr. Dwyer added that the launch of Exousia Health is expected to include a third, synergistic revenue stream - the addition of a compounding pharmacy to its operations, allowing Exousia Health doctors to submit patient prescriptions directly to the company's pharmacy, thereby capturing additional revenue.

About the Telehealth Market

The telehealth market is a major sector of the global economy, with a projected market size exceeding $500 billion by 2030. Fueled by increasing consumer demand for convenient healthcare, advancements in technology, and favorable regulatory changes, telehealth has become an essential component of modern healthcare delivery.

About Us

Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.

For more information, please visit: www.exousiapro.com

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE: Exousia Pro, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the expected monthly revenue for Exousia Pro's (MAJI) new telehealth division?

Exousia Health is expected to generate $50,000 in monthly revenue initially from its base of 1,000 active clients, with potential for significant increase from two additional contracts under review.

How many active clients will Exousia Pro's (MAJI) telehealth division have at launch?

The new Exousia Health division will start with 1,000 active clients following the completion of the telehealth company acquisition.

What are the revenue streams for Exousia Pro's (MAJI) new telehealth division?

Exousia Health will have three revenue streams: patient-doctor consultations, markup on prescribed regimens, and a compounding pharmacy operation for direct prescription fulfillment.

How long will it take Exousia Pro (MAJI) to implement its new telehealth contracts?

The company plans to onboard the two large contracts over a 12-month period to ensure seamless client transition and effective operational scaling.

What is Exousia Pro's (MAJI) strategy for the telehealth division expansion?

The company is implementing a three-pronged approach: acquiring an existing telehealth platform, securing two additional major contracts, and integrating a compounding pharmacy operation.